CP 55,940

CP 55,940 is a synthetic cannabinoid that was developed in the 1970s by the pharmaceutical company Pfizer. It is a potent agonist of the cannabinoid receptors, specifically the CB1 receptor and CB2 receptor. CP 55,940 is often used in scientific research to study the endocannabinoid system and its effects on the body.
Chemical Structure and Properties[edit]
CP 55,940 is a bicyclic compound with a complex structure that includes a cyclohexane ring and a phenol group. The chemical formula of CP 55,940 is C23H32O2, and it has a molecular weight of 340.5 g/mol. The compound is lipophilic, allowing it to easily cross the blood-brain barrier and interact with cannabinoid receptors in the central nervous system.
Mechanism of Action[edit]
CP 55,940 acts as a full agonist at both the CB1 and CB2 receptors. These receptors are part of the G protein-coupled receptor family and are primarily involved in modulating neurotransmitter release in the brain. Activation of CB1 receptors by CP 55,940 leads to a decrease in neurotransmitter release, which can result in effects such as analgesia, sedation, and appetite stimulation.
Research Applications[edit]
CP 55,940 is widely used in research to explore the physiological and pharmacological roles of the endocannabinoid system. It is often employed in studies investigating the effects of cannabinoids on pain, inflammation, and neurodegenerative diseases. Additionally, CP 55,940 is used to study the potential therapeutic applications of cannabinoids in conditions such as multiple sclerosis, epilepsy, and cancer.
Safety and Toxicity[edit]
As a research chemical, CP 55,940 is not intended for human consumption. Studies have shown that it can produce effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. However, due to its potency, CP 55,940 can also lead to more pronounced side effects, including anxiety, paranoia, and tachycardia.
Related Pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian